Since the listing on the HKEx GEM in 2002, the Group has expanded its business operation and scope. During the 2000s, the Group has expanded its operations to include the commercialization of mature licensed-in products from United States, Europe and other countries and has broadened its business scope to include other therapeutic areas such as paediatrics, woman health, rare diseases, dermatology, obstetrics, urology, oncology and ophthalmology.

Following the transfer of listing to the HKEx Main Board in 2010, the Group continued to scale up its business. During the 2010s and up to date, the Group has expanded its production facilities to include the production of topical gel, lyophilized powder for injection, small volume parenteral solutions and eye gel products in Hefei and the production of medical device and inhale formulation, solid dosage formulation and ophthalmic products in Guangzhou. Currently, the Group has capability for developing and providing full range of pharmaceutical products.